Peter C. Farrell, a director of ResMed Inc, filed a Form 4 on November 21, 2026, reporting the acquisition of 554 restricted stock units in ResMed common stock on November 19, 2026, at a price of $0.
Key Highlights
- Reporting person: Peter C. Farrell, identified in the filing as a director and chairman emeritus of ResMed Inc (NYSE:RMD).
- Transaction: 554 shares of ResMed Common Stock acquired (transaction code A) on November 19, 2026, at a price of $0.
- Security type: The shares represent Restricted Stock Units (RSUs), according to the filing's footnote.
- Vesting schedule: The RSUs vest in full on the earlier of November 11, 2027, or the annual meeting of stockholders in the year following the grant date.
- Post-transaction ownership: Following the transaction, Farrell beneficially owned 52,188 shares of ResMed Common Stock directly.
Peter C. Farrell RSU Award: Transaction and Ownership Details
According to the filing, Peter C. Farrell, serving as a director of ResMed Inc, reported the acquisition of 554 shares of ResMed Common Stock on November 19, 2026. The transaction was coded "A" (acquired) and carried a reported price of $0, consistent with an RSU award rather than an open-market purchase. The filing identifies Farrell's role as chairman emeritus and lists his address as 9001 Spectrum Center Blvd., San Diego, California 92123.
The filing's footnote states that the shares awarded represent Restricted Stock Units and that they "vest in full on the earlier of 11/11/2027, or the annual meeting of stockholders in the year following the grant date." No derivative securities were reported in Table II. The form was filed by one reporting person and was not marked as an amendment to a prior filing.
Following the reported transaction, Farrell's direct beneficial ownership of ResMed Common Stock stood at 52,188 shares, as disclosed in Table I of the filing. The Form 4 was signed by Peter C. Farrell and dated November 21, 2026, two days after the date of the earliest transaction.
What Was Disclosed
ResMed Inc director and chairman emeritus Peter C. Farrell reported the acquisition of 554 RSUs in ResMed Common Stock on November 19, 2026, at $0, bringing his direct beneficial ownership to 52,188 shares. The RSUs are scheduled to vest no later than November 11, 2027.




Please wait processing your request...